ESWL: Ultraslow SWL Versus Slow SWL for Ureteric Stones With High Attenuation Value

Sponsor
Cairo University (Other)
Overall Status
Completed
CT.gov ID
NCT03795545
Collaborator
Beni-Suef University (Other)
101
1
2
7
14.4

Study Details

Study Description

Brief Summary

Ultraslow full-power SWL versus slow power-ramping SWL in ureteric stones with high attenuation value

Condition or Disease Intervention/Treatment Phase
  • Procedure: SWL
N/A

Detailed Description

To evaluate the efficacy of ultraslow rate of SWL versus slow rate, power ramping SWL

Study Design

Study Type:
Interventional
Actual Enrollment :
101 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Ultraslow Full-power SWL Versus Slow SWL in Stones With High Attenuation Value
Actual Study Start Date :
Jan 11, 2019
Actual Primary Completion Date :
Jul 16, 2019
Actual Study Completion Date :
Aug 12, 2019

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Ultraslow shock wave lithotripsy (SWL)

SWL at ultraslow rate of 30 SW/min. Power ramping at the first 100 SW from 6 to 18 kv followed by safety pause for two minutes then power ramping from 18 to 22kv during the second 100 SW followed by safety pause for another two minutes. The rest of the session at 22kv (full power).

Procedure: SWL
Shock wave lithotripsy
Other Names:
  • ESWL
  • Active Comparator: Slow power-ramping SWL

    SWL at a slow rate of 60 SW/min. Power ramping from 6 - 10 kv during the first 500 SW then from 11 - 14 kv during the second 500 SW then from 15 - 18 kv during the following 500 SW then from 19 - 22 kv during the remaining 1000 - 1500 SW.

    Procedure: SWL
    Shock wave lithotripsy
    Other Names:
  • ESWL
  • Outcome Measures

    Primary Outcome Measures

    1. stone free rate [3 months following last session of SWL]

      Complete clearance of stones in addition to clinically insignificant residual fragments

    Secondary Outcome Measures

    1. Complications rate [3 months following last session of SWL]

      Comparison of rate of complications in both groups

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • single upper ureteric stone less than or equal to 2 cm

    • radio-opaque stone

    • high attenuation value (≥ 1000 HU) stone

    Exclusion Criteria:
    • Abnormal renal anatomy

    • renal insufficiency

    • solitary kidney

    • coagulopathies

    • uncontrolled hypertension

    • renal artery or aortic aneurysm

    • active urinary tract infection

    • pregnancy

    • severe skeletal malformations (spinal deformity) precluding proper stone localization

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Beni-Suef Hospitals Banī Suwayf Outside U.S./Canada Egypt

    Sponsors and Collaborators

    • Cairo University
    • Beni-Suef University

    Investigators

    • Study Director: Ahmad Aref Al-Dessoukey, Ass. Prof., Beni-Suef University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Mohammed Said ElSheemy, Associate Professor of Urology, Cairo University
    ClinicalTrials.gov Identifier:
    NCT03795545
    Other Study ID Numbers:
    • 16231
    First Posted:
    Jan 7, 2019
    Last Update Posted:
    Dec 10, 2019
    Last Verified:
    Dec 1, 2019
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Mohammed Said ElSheemy, Associate Professor of Urology, Cairo University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Dec 10, 2019